Johnson & Johnson

$149.69

+2.72 (+0.03%) Today
1 Day1D

5 Days5D

1 Month1M

6 Months6M

YTDYTD

1 Year1Y

2 Years2Y

5 Years5Y

MaxMax

About

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

CEO

Alex Gorsky

Employees

132200

Headquarters

One Johnson & Johnson Plaza New Brunswick, NJ, 08933

Founded

1886

Market Cap

Johnson & Johnson News

J&J’s Ethicon touts surgical stapler study Aug 06, 2020

Ethicon — part of Johnson & Johnson (NYSE:JNJ) — is highlighting new study results in which its Echelon powered stapler with gripping surface technology (GST) had a lower rate of bleeding-related complications than a competing Medtronic product. Ethicon funded the peer-reviewed study, which appears online in Medical Devices: Evidence and Research. The study compared the Echelon…

J&J’s Ethicon touts surgical stapler study Aug 06, 2020

Ethicon — part of Johnson & Johnson (NYSE:JNJ) — is highlighting new study results in which its Echelon powered stapler with gripping surface technology (GST) had a lower rate of bleeding-related complications than a competing Medtronic product. Ethicon funded the peer-reviewed study, which appears online in Medical Devices: Evidence and Research. The study compared the Echelon […]

J&J starts clinical trial on vaccine candidate after strong non-human results Aug 03, 2020

Johnson & Johnson (NYSE:JNJ) announced that its lead SARS-CoV-2 vaccine candidate protected against infection of the virus causing COVID-19 in pre-clinical studies. New Brunswick, N.J.-based J&J published data in Nature that showed the company’s investigational adenovirus serotype 26 (Ad26), vector-based vaccine elicited a robust immune response with “neutralizing antibodies” to prevent subsequent infection and provide complete or…

MedTech 100 roundup: Industry hits pandemic peak Jul 20, 2020

After five months since medtech stocks peaked before the COVID-19 pandemic rocked the markets, the industry inched back toward that pre-pandemic high. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 88.9 points at the end of last week (July 17). That total represents just a -3.7% […]

Johnson & Johnson to take its time on general surgery robot Jul 17, 2020

Johnson & Johnson (NYSE:JNJ)  has decided not to follow a 510(k) clearance pathway for its planned general surgery robot — with a goal to start first-in-human studies with the system by the second half of 2022. That was one of the major pieces of information to come out of the New Brunswick, N.J.–based company’s quarterly earnings […]